BioScience Managers Limited

Acrux Limited is a specialty pharmaceutical company based in West Melbourne, Australia, focused on developing and commercializing generic and specialty topical pharmaceuticals. The company offers a range of testosterone solutions, including oral tablets, buccal tablets, subcutaneous pellets, transdermal patches, injections, and topical gels aimed at treating adult males with low or no testosterone. Additionally, Acrux provides estradiol sprays under the Evamist and Lenzetto brand names for managing menopause-related flushes in women. The company's innovative drug delivery technology allows for the administration of medications through the skin, and its product pipeline includes treatments for hormonal deficiencies, pain, central nervous system disorders, and contraceptives. With extensive clinical experience, Acrux has completed numerous human trials for its products, positioning itself as a key player in the global pharmaceutical market.

Cynata Therapeutics Limited is an Australian company focused on developing and commercializing its proprietary Cymerus™ mesenchymal stem cell technology for therapeutic applications. The company’s lead product candidate, CYP-001, has completed Phase I clinical trials aimed at treating graft versus host disease. In addition to this, Cynata is exploring treatments for various conditions such as asthma, heart attack, diabetic wounds, coronary artery disease, and acute respiratory distress syndrome, among others, which are currently in preclinical stages. The Cymerus technology utilizes induced pluripotent stem cells (iPSCs) derived from adult donors, enabling the efficient and scalable production of mesenchymal stem cells. This innovative approach addresses existing limitations in stem cell manufacturing, allowing for virtually limitless quantities of therapeutic cells without the need for continuous donor sourcing. Cynata collaborates with several prestigious institutions, including Monash University and Massachusetts General Hospital, to advance its research and development efforts. Founded in 2011 and based in Carlton, Australia, Cynata is positioned to significantly contribute to the field of regenerative medicine.

Adherium Limited is a developer and manufacturer of digital health technologies aimed at improving medication adherence for patients with chronic diseases, particularly asthma and chronic obstructive pulmonary disease (COPD). The company offers Hailie, a medication adherence solution that includes smart device sensors that attach to existing inhalers and a mobile app for tracking medication usage. This technology enables patients, caregivers, and healthcare professionals to monitor adherence, set reminders, and analyze medication patterns. Adherium's products are designed to enhance health outcomes and reduce healthcare costs by addressing sub-optimal medication use. The company operates primarily in Europe, with additional markets in New Zealand, Australia, North America, and Asia. Founded in 2001 and headquartered in Auckland, New Zealand, Adherium also collaborates with healthcare organizations, including a partnership with HGE Health focused on COPD management.

We are a North American company, whose mission is to provide high quality medications for those patients who need them to treat their disease by making the medicine accessible to everyone. Our reason for being is to close the gap between pharmaceutical manufacturers and patients around the world whose quality of life depends on receiving the right treatment at the right place and time. At Pharmaxis Group we believe that working closely with our customers, employees, shareholders and key partners allows us to provide exceptional value in all the services we provide. Specialized in the supply of drugs that are difficult to find in the fields of oncological, immunological, orphan diseases among others. Our global network of pharmaceutical suppliers, combined with our strong logistics network, includes certified partners in good storage and handling practices, and good manufacturing practices, all necessary to properly guarantee high quality in all the products and services.

Canary Medical Inc. focuses on developing innovative medical implant and data management devices that facilitate remote patient monitoring and data collection. Founded in 2013 and based in Vancouver, Canada, the company has created the Canary Health Implantable Reporting Processor (CHIRP), a sensor-based device that autonomously gathers medical data without requiring significant patient compliance or physician intervention. In 2021, it launched canturio™te, the first "smart knee" tibial extension, which continuously monitors patient activity and joint performance, transmitting the collected data to the cloud. Canary Medical aims to enhance healthcare outcomes while reducing costs by providing reliable and efficient healthcare data monitoring and analysis. The company is backed by a team of experienced professionals with expertise in medical device design, development, and data informatics.

Immunosis is a biotechnology company focused on developing advanced genetic technologies aimed at the early detection of Primary Immune Deficiency (PID). The company has created a proprietary diagnostic test that utilizes genetic information to identify patients with PID. This innovative approach is designed to expedite the diagnostic process, allowing for quicker identification of immune deficiencies. By improving the speed and accuracy of diagnosis, Immunosis enables patients to receive timely medical care, ultimately facilitating better health outcomes and recovery for those affected by immune deficiency conditions.

Rex Bionics Ltd. is a New Zealand-based company that specializes in the development and manufacturing of robotic medical equipment aimed at rehabilitation. Incorporated in 2007, the company produces the REX, a hands-free robotic device designed to assist individuals with mobility impairments in exercising, walking, and standing. Rex Bionics focuses on improving the physical and psychological well-being of people affected by spinal cord injuries, strokes, traumatic brain injuries, and neurodegenerative diseases. The company's primary products include the REX and the REX P (Personal), which cater to both professional neuro-rehabilitation clinics and personal homecare markets. Through innovative technology, Rex Bionics aims to enhance the rehabilitation experience for individuals facing significant mobility challenges.

Rex Bionics Ltd. is a New Zealand-based company that specializes in the development and manufacturing of robotic medical equipment aimed at rehabilitation. Incorporated in 2007, the company produces the REX, a hands-free robotic device designed to assist individuals with mobility impairments in exercising, walking, and standing. Rex Bionics focuses on improving the physical and psychological well-being of people affected by spinal cord injuries, strokes, traumatic brain injuries, and neurodegenerative diseases. The company's primary products include the REX and the REX P (Personal), which cater to both professional neuro-rehabilitation clinics and personal homecare markets. Through innovative technology, Rex Bionics aims to enhance the rehabilitation experience for individuals facing significant mobility challenges.

Avita Medical Inc. is a commercial-stage regenerative tissue company headquartered in Valencia, California, specializing in innovative treatment solutions for burn injuries, chronic wounds, and dermatological conditions. The company leverages its proprietary technology to harness the regenerative properties of a patient’s own skin, with its lead product being the RECELL System. This device allows healthcare professionals to create a suspension of Spray-On Skin cells from a small sample of the patient's skin, facilitating the treatment of acute thermal burns in adults. Avita is currently focusing its efforts on the U.S. market, where the RECELL System is being rolled out across approximately 136 burn centers, while also exploring clinical trials for expanded indications, including pediatric applications and soft-tissue reconstruction. The company has established research collaborations with various institutions to advance its development initiatives, including potential treatments for conditions like epidermolysis bullosa and skin rejuvenation.

Saluda Medical is a commercial-stage medical device company focused on developing innovative treatments for chronic neurological conditions, particularly chronic neuropathic pain. The company utilizes a unique closed-loop neuromodulation platform that senses and measures neural responses to stimulation. This technology automatically adjusts the therapy based on real-time neurophysiological feedback, allowing for personalized treatment tailored to each patient's specific needs. By monitoring the patient's neural fingerprint, Saluda Medical’s devices enable the precise delivery of electrical stimulation, ultimately improving the management of chronic back pain and enhancing patient outcomes.

HeartWare International, Inc. specializes in the development and manufacturing of small implantable heart pumps, also known as ventricular assist devices, aimed at treating advanced heart failure. The company offers the HeartWare Ventricular Assist System, which comprises a left ventricular assist device, patient accessories, and surgical tools designed to provide critical circulatory support for patients in the advanced stages of heart failure. Additionally, HeartWare is working on the Miniaturized Ventricular Assist Device, intended for chronic heart failure patients. The company markets its products through clinical studies in the United States and directly to cardiac centers and hospitals worldwide. Headquartered in Framingham, Massachusetts, HeartWare is committed to improving the quality of life for patients suffering from severe heart conditions.

Bionomics Limited is a clinical-stage biopharmaceutical company based in Thebarton, Australia, specializing in the discovery and development of innovative therapeutics for central nervous system disorders and cancer. The company's portfolio includes several drug candidates, with its lead product, BNC210, a negative allosteric modulator aimed at treating anxiety, panic, agitation, and post-traumatic stress disorder, having completed a phase 2 clinical trial. Additionally, Bionomics is developing BNC375, targeting cognitive impairment in Alzheimer's disease, and BNC101, a monoclonal antibody that has completed phase 1 trials aimed at cancer stem cells. The company is also advancing BNC105, a vascular disrupting agent currently undergoing phase 2 trials for refractory colorectal cancer and phase 1 trials for relapsed/refractory chronic lymphocytic leukemia. Bionomics further enhances its capabilities through the ionX platform, which integrates genomics discoveries and technologies. Founded in 1996, the company has established strategic partnerships to bolster its research and development efforts.

Peplin is a development-stage specialty pharmaceutical company that focuses on advancing and commercializing medical dermatology products. The company's lead product candidate is PEP005, a patient-applied topical gel derived from the plant Euphorbia peplus, designed to treat actinic keratosis. PEP005 is currently in Phase III clinical trials. In addition to this, Peplin is also developing a physician-applied formulation of PEP005 for the treatment of superficial basal cell carcinoma. The active compound in both formulations is a small molecule extracted and purified from the sap of Euphorbia peplus. Peplin further expanded its capabilities in the dermatology sector by acquiring Neosil, Inc. in 2008, and was subsequently acquired by LEO Pharma A/S.

Arana Therapeutics is a biopharmaceutical company dedicated to developing next-generation antibody-based treatments for inflammatory diseases and cancer. The company specializes in creating antibody and peptide products aimed at addressing these significant health challenges. Through its innovative approach, Arana Therapeutics seeks to enhance therapeutic options available for patients suffering from these conditions.

Acrux Limited is a specialty pharmaceutical company based in West Melbourne, Australia, focused on developing and commercializing generic and specialty topical pharmaceuticals. The company offers a range of testosterone solutions, including oral tablets, buccal tablets, subcutaneous pellets, transdermal patches, injections, and topical gels aimed at treating adult males with low or no testosterone. Additionally, Acrux provides estradiol sprays under the Evamist and Lenzetto brand names for managing menopause-related flushes in women. The company's innovative drug delivery technology allows for the administration of medications through the skin, and its product pipeline includes treatments for hormonal deficiencies, pain, central nervous system disorders, and contraceptives. With extensive clinical experience, Acrux has completed numerous human trials for its products, positioning itself as a key player in the global pharmaceutical market.

Nexvet Australia Pty Ltd is a biopharmaceutical company based in Melbourne, Australia, specializing in the development of biological therapies for companion animals. Founded in 2010, Nexvet focuses on creating species-specific monoclonal antibodies to address chronic pain, immune oncology, chronic inflammation, and allergies in pets. The company's key products include Ranevetmab and Frunevetmab, which target nerve growth factor to alleviate pain associated with osteoarthritis in dogs and degenerative joint disease in cats, respectively. Additionally, Nexvet is developing NV-03, a monoclonal antibody for chronic joint pain in horses. Utilizing a unique technology called PETisation, Nexvet customizes therapies to specific species, enhancing the effectiveness and safety of treatments while minimizing immune responses. As a subsidiary of Zoetis Inc., Nexvet aims to transform animal medicine by collaborating with global partners in veterinary and human health to advance its innovative pipeline.

AmpliPhi Biosciences is a biopharmaceutical company that specializes in developing bacteriophage-based therapies for bacterial infections. By utilizing naturally occurring viruses known as bacteriophages, the company aims to address various bacterial infections, particularly those caused by drug-resistant strains prevalent in hospital environments. AmpliPhi has established a drug development and manufacturing platform that enables the rapid creation and production of multiple phage-based therapies. The company’s initial focus is on treating acute and chronic infections affecting the lungs, sinuses, and gastrointestinal tract. With operations in Richmond, Virginia, Colworth Science Park near London, and outside Sydney, Australia, AmpliPhi is committed to advancing its pipeline of phage therapies to effectively combat targeted bacterial diseases.

Alchemia Limited is an Australian biopharmaceutical company that focuses on developing innovative medical treatments. The company has an FDA-approved drug, Fondaparinux sodium, and is advancing a late-stage oncology product pipeline based on its proprietary HyACT platform. In addition to its therapeutic products, Alchemia possesses a drug discovery platform known as VAST®, which leverages its expertise in chemistry to create new drug candidates. Through these initiatives, Alchemia aims to address unmet medical needs and contribute to advancements in healthcare.

Adherium Limited is a developer and manufacturer of digital health technologies aimed at improving medication adherence for patients with chronic diseases, particularly asthma and chronic obstructive pulmonary disease (COPD). The company offers Hailie, a medication adherence solution that includes smart device sensors that attach to existing inhalers and a mobile app for tracking medication usage. This technology enables patients, caregivers, and healthcare professionals to monitor adherence, set reminders, and analyze medication patterns. Adherium's products are designed to enhance health outcomes and reduce healthcare costs by addressing sub-optimal medication use. The company operates primarily in Europe, with additional markets in New Zealand, Australia, North America, and Asia. Founded in 2001 and headquartered in Auckland, New Zealand, Adherium also collaborates with healthcare organizations, including a partnership with HGE Health focused on COPD management.

SeaDragon Limited, based in Nelson, New Zealand, specializes in the manufacture and marketing of refined fish oils. Established in 1986, the company processes fish oils into marine bioactive compounds and offers a range of Omega-2 and Omega-3 products. Omega-2 is sourced from both animal and vegetable sources, serving industries such as cosmetics, nutraceuticals, and pharmaceuticals, while Omega-3 products are derived from tuna and marine-farmed salmon. SeaDragon primarily caters to health supplement manufacturers, delivering high-quality refined oils that meet industry standards.

Avita Medical Inc. is a commercial-stage regenerative tissue company headquartered in Valencia, California, specializing in innovative treatment solutions for burn injuries, chronic wounds, and dermatological conditions. The company leverages its proprietary technology to harness the regenerative properties of a patient’s own skin, with its lead product being the RECELL System. This device allows healthcare professionals to create a suspension of Spray-On Skin cells from a small sample of the patient's skin, facilitating the treatment of acute thermal burns in adults. Avita is currently focusing its efforts on the U.S. market, where the RECELL System is being rolled out across approximately 136 burn centers, while also exploring clinical trials for expanded indications, including pediatric applications and soft-tissue reconstruction. The company has established research collaborations with various institutions to advance its development initiatives, including potential treatments for conditions like epidermolysis bullosa and skin rejuvenation.

Millenium Biologix Corporation is a biomedical company based in Kingston, Canada, primarily focused on the development and commercialization of implantable medical devices and skeletal tissue regeneration products for orthopedic applications in the United States and Europe. The company offers Skelite, a synthetic bone graft designed for healing and replacement, alongside products such as Primacoll and Peptos, which are aimed at stimulating bone tissue growth. Additionally, Millenium Biologix has developed ACTES, an advanced cell culture and tissue engineering system that provides automated control over biological processes involved in tissue engineering. Established in 1986, the company continues to innovate within the biomedical field.

Millenium Biologix Corporation is a biomedical company based in Kingston, Canada, primarily focused on the development and commercialization of implantable medical devices and skeletal tissue regeneration products for orthopedic applications in the United States and Europe. The company offers Skelite, a synthetic bone graft designed for healing and replacement, alongside products such as Primacoll and Peptos, which are aimed at stimulating bone tissue growth. Additionally, Millenium Biologix has developed ACTES, an advanced cell culture and tissue engineering system that provides automated control over biological processes involved in tissue engineering. Established in 1986, the company continues to innovate within the biomedical field.